David Trachtenbarg, MD
Family Medicine · Peoria, ILNPI 1952318719
Payments from drug & device makers
Across 469 payments — averaging $648.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$173K
- Applied Therapeutics, Inc.$68K
- Biogen$42K
- Novo Nordisk$16K
- Abbott$810
- Sanofi-aventis U.S. LLC$798
- plus $3K from 26 others
What the payments were for
- Consulting fees$13,26052%
- Travel & lodging$5,26221%
- Food & beverage$6,95227%
- Education$1371%
- Other$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 185 | $173,202 |
| Applied Therapeutics, Inc. | 18 | $67,849 |
| Biogen | 10 | $42,039 |
| Novo Nordisk | 36 | $16,214 |
| Abbott | 31 | $810 |
| Sanofi-aventis U.S. LLC | 33 | $798 |
| Dexcom, Inc. | 15 | $394 |
| Boehringer Ingelheim | 16 | $379 |
| AstraZeneca(2 entities) | 14 | $325 |
| Medtronic(2 entities) | 13 | $317 |
| Lilly USA, LLC | 20 | $303 |
| Insulet Corporation | 13 | $286 |
| Amgen | 14 | $235 |
| Tandem Diabetes Care, Inc. | 6 | $158 |
| Radius Health, Inc. | 8 | $133 |
| Xeris Pharmaceuticals, Inc. | 6 | $125 |
| Sanofi Pasteur Inc. | 1 | $111 |
| Senseonics, Incorporated | 2 | $92 |
| Companion Medical, Inc. | 2 | $81 |
| Coloplast | 1 | $74 |
| Corcept Therapeutics | 4 | $73 |
| Shire North American Group Inc | 4 | $61 |
| AbbVie | 3 | $56 |
| Johnson & Johnson | 3 | $44 |
| Nestle Healthcare Nutrition Inc. | 3 | $40 |
| Valeritas, Inc. | 2 | $36 |
| Zealand Pharma US, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Bayer | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Lifescan, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$13,374
- RYBELSUS$2,040
- Ozempic$1,679
- Tresiba$955
- FREESTYLE LIBRE 3$407
- DISEASE STATE$236
- JARDIANCE$125
- DEXCOM G7 GSS (161)$111
- SOLIQUA 100/33$103
- Wegovy$100
How this compares
$304,367 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 201 | $273,806 |
| JardianceEmpagliflozin | 145 | $135,233 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $76,360 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 49 | $66,343 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $60,589 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $45,118 |
| MounjaroTirzepatide | 33 | $37,426 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $34,958 |
| Tresiba Flextouch U-100Insulin Degludec | 57 | $31,123 |
| TrulicityDulaglutide | 22 | $29,198 |
| RybelsusSemaglutide | 25 | $24,101 |
| Novolog FlexpenInsulin Aspart | 71 | $17,749 |
| FarxigaDapagliflozin Propanediol | 15 | $17,448 |
| Bydureon BciseExenatide Microspheres | 23 | $17,423 |
| NovologInsulin Aspart | 55 | $16,464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $16,214 | $314,372281 claims |
| Boehringer IngelheimJardiance, Tradjenta | $379 | $145,524157 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30 | $303 | $72,09779 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $798 | $69,70361 claims |
| AstraZenecaFarxiga | $325 | $17,44815 claims |
| Johnson & JohnsonInvokana | $44 | $9,16315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Peoria
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.